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Nadya Velikova1,6,*, Simone Fulle2,†,*, Ana Sousa Manso3,4, Milena Mechkarska5, Paul Finn2, 
J. Michael Conlon5, Marco Rinaldo Oggioni3,4, Jerry M. Wells6 & Alberto Marina1,7
Novel antibacterials are urgently needed to address the growing problem of bacterial resistance 
to conventional antibiotics. Two-component systems (TCS) are widely used by bacteria to regulate 
gene expression in response to various environmental stimuli and physiological stress and have been 
previously proposed as promising antibacterial targets. TCS consist of a sensor histidine kinase (HK) and 
an effector response regulator. The HK component contains a highly conserved ATP-binding site that 
is considered to be a promising target for broad-spectrum antibacterial drugs. Here, we describe the 
identification of putative HK autophosphorylation inhibitors following two independent experimental 
approaches: in vitro fragment-based screen via differential scanning fluorimetry and in silico structure-
based screening, each followed up by the exploration of analogue compounds as identified by ligand-
based similarity searches. Nine of the tested compounds showed antibacterial effect against multi-drug 
resistant clinical isolates of bacterial pathogens and include three novel scaffolds, which have not been 
explored so far in other antibacterial compounds. Overall, putative HK autophosphorylation inhibitors 
were found that together provide a promising starting point for further optimization as antibacterials.
Bacterial multi-drug resistance (MDR) is defined as acquisition by pathogenic bacteria of non-susceptibility to at 
least one agent in three categories of antibacterials1. MDR is a growing problem worldwide2 and has led the World 
Health Organization (WHO) to classify antibacterial resistance and the antibiotics crisis to be a health problem 
“bigger than AIDS”. The so-called “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) are the main cause of hospital 
infections and are resistant to virtually all currently marketed antibiotics3. The aging population and growing 
number of immunocompromised patients due to HIV, cancer therapy or transplantation have increased the pop-
ulation susceptibility to bacterial infections making the need for novel antibacterials even more acute. At the same 
time, MDR represent an economical problem since infections due to resistant bacteria have 1.3–2 fold higher 
associated healthcare costs than susceptible bacteria due to increased mortality, morbidity and treatment costs4.
Bacterial two-component systems (TCS) have been proposed as promising targets for the discovery of novel 
antibacterials with a new mechanism of action and with lower potential of resistance development in comparison 
with conventional antibiotics5,6. TCS are signal transduction devices used by nearly all bacteria that regulate a 
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variety of processes including bacterial growth, cell-wall metabolism, virulence, biofilm formation and resist-
ance to antibiotics7,8. A prototypical TCS consist of a membrane bound histidine kinase (HK) and its cognate 
response regulator (RR). Upon sensing an environmental stimulus the HK is autophosphorylated on conserved 
histidine residues in the dimerization and histidine phosphotransfer (DHp) domain by an ATP molecule binding 
to the catalytic and ATP-binding (CA) domain. Subsequently, the phosphoryl group from the His is transferred 
to a conserved aspartic acid residue in the receiver (REC) domain of the RR. The phosphorylated state of the 
RR affects its binding affinity to a cognate DNA motif and/or other protein partners, thereby modulating tran-
scription of target genes8. HK autophosphorylation inhibitors (HKAIs) targeted at the CA domains of HKs are 
expected and were recently shown to simultaneously inhibit multiple TCS due to the conservation between the 
HK CA domains6,9. Furthermore, the CA domain fold of the HKs is completely different to the fold found in 
mammalian Ser/Thr/Tyr kinases10,8, providing the inhibitors targeting CA domain selectivity for HKs and reduc-
ing the probability of potential side effects.
So far, TCS inhibitors have been discovered mainly by in vitro high-throughput screening (HTS)11–13 or by 
structure-based virtual screening (SBVS) experiments14–18. SBVS is nowadays an indispensable component within 
drug discovery efforts, including hit identification and optimization14–22. Alternatively, fragment-based screening 
(FBS) has become increasingly popular over the last 10 years because it allows an efficient exploration of chemical 
space and results into smaller hit compounds, which can be later optimized (e.g. regarding affinity or physico-
chemical properties)23–25. FBS can be done, for example, by soaking experiments via X-ray crystallography or by 
differential scanning fluorimetry (DSF) where the change of denaturation temperature of a protein is monitored 
in different conditions, including the presence of low-molecular weight ligands26,27.
Here, we report a step-wise application of the two complementary screening approaches mentioned above, 
i.e. in silico screening of small molecules and in vitro FBS by DSF, to identify putative HKAIs. The resulting hits 
are further explored by analogue compounds, as identified by ligand-based similarity searches (LBSS) of a public 
repository database. Both approaches yielded molecules that were capable to inhibit different HKs in vitro, and 
which showed antibacterial activity against laboratory strains and, even more valuable, against MDR clinical 
isolates, including methicillin-resistant Staphylococcus aureus (MRSA).
Results and Discussion
Two putative fragment-like HKAIs identified by in vitro screening. To identify compounds with 
broad capacity to inhibit HK autophosphorylation we targeted the catalytic domain of HKs following two 
approaches. First, 898 fragment-like ligands (MW < 300, ClogP < 3, number of hydrogen bond donors and 
hydrogen bond acceptors < 3, number of rotatable bonds < 328) of the Fragment Library 1 from Chem-X-Infinity 
(Romanville, France) were screened for binding to the CA domains of HKs via differential scanning fluorime-
try (DSF)27 (Figs S1 and S2). As targets, we selected the HKs of two essential TCS, WalK-WalR of Streptococcus 
pneumonia29 and NblS-RapB of Synechococcus sp. PCC 794230 (Fig. S1A). The presence of 4-(4-bromophe-
nyl)-1,3-thiazol-2-amine (F1, Fig. 1) and 2-hydroxy-carbazole (F2) increased the temperature at which HK NblS 
(CA domain) unfolds (Tm) by 2.1 and 2.2 °C, respectively, suggesting that F1 and F2 are ligands for the CA 
domain of NblS (Fig. S2). Encouragingly, the screening for ligands of HK WalK (DHp and CA domain) showed 
that F1 and F2 were also among the hits increasing WalK Tm. F1 and F2 increased WalK Tm by 4.5 and 3.9 °C, 
respectively (Fig. S2). To test the HK inhibitory capacity of these compounds we carried out autophosphorylation 
assays with the radiolabeled γ -32P-ATP substrate. Since fragments usually show low affinity for their targets31,28, 
the assays were performed at high compound concentration to minimize the probability of discarding potential 
inhibitors with weak binding capacity. In the autophosphorylation reaction the HK also works as substrate and 
it was observed for several HKs that the reaction reaches saturation in short time, even more due to the accumu-
lation of the product ADP that has inhibitory activity32–34. Therefore, to assure the linearity of the autophospho-
rylation reaction in respect to time and to maximize the effect of the putative inhibitors we initially checked the 
inhibitory capacity of these fragments to a single and high concentration (5 mM) at one short time point (30 sec). 
The assays showed that F1 and F2 have a weak inhibitory capacity for the autophosphorylation activity of the 
screened catalytic portion of WalK. However, F1 and F2 inhibited the autophosphorylation of PhoR from the 
Gram-negative Escherichia coli (PhoRE), with IC50 ≈ 2 mM (the compound showed limited solubility in kinase 
buffer) and 0.3 mM, respectively (Table 1, Fig. 2) suggesting HK inhibitory activity. Furthermore, F1 and F2 
showed antibacterial effect against the Gram-positive S. aureus DSM 20231 with minimal inhibitory concen-
trations (MIC) of 25 and 31 μ g/ml, respectively (Tables 1 and 2). F1 showed also antibacterial effect against S. 
epidermidis DSM 20044 with a MIC of 4 μ g/ml.
Structure-based virtual screening reveals two drug-like putative HKAIs. The ATP-binding pocket 
of the CA domains of HKs has been previously used in SBVS14. In virtual screening, both ligand and receptor 
flexibility should be considered. While the consideration of the ligand flexibility is straightforward35,36, the con-
sideration of the receptor flexibility remains a major challenge for docking calculations37,38. However, docking 
into an ensemble of receptor structures has been shown to be a valuable mean to cope implicit with the recep-
tor flexibility39–41. With that in mind, to identify drug-like ligands (MW < 500, ClogP ≤ 5, number of hydro-
gen bond donors ≤ 5, number of hydrogen bond acceptors ≤ 1042) of the ATP-binding sites of multiple HK CA 
domains, a diverse set of 600 000 drug-like compounds was screened via in silico docking calculation using as 
target receptors the ATP-binding sites of the CA domains of three different HKs: T. maritima HK853 (PDB: 
3DGE)32, T. maritima CheA (PDB: 1I58)43 and G. stearothermophilus KinB (PDB: 3D36)44 (Fig. S1B). These three 
CA domains were selected because the structures were solved in the presence of a nucleotide and re-docking of 
the cognate ligand was successful (RMSD docked vs experimental nucleotide of 1 Å for 3DGE and 3D36, and 3 Å 
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for 1I58). Furthermore, virtual screening with the three HK structures, that have some sequence variability at the 
ATP-binding site, was expected to facilitate the identification of general HKAIs.
It has been shown to be valuable to rescore docking solutions by ligand efficiency (l.e.) metrics as well as more 
rigorous rescoring approaches such as free energy perturbation (FEP), molecular mechanics Poisson-Boltzmann 
surface area (MM-PBSA) or linear interaction energy (LIE)45–47. However, the application of default protocols 
for binding free energy calculations can also lead to only moderate ligand rankings because it is recommended 
to identify the best procedure in a specific case48. Such a validation step is clearly hindered for rather unexplored 
targets such as the HKs used in the in silico screening reported here. Therefore, the screened compounds were 
ranked based on the raw docking score, ChemPLP49, as well as ligand efficiency (l.e.)50. The top 100 docked com-
pounds in common for the three HKs were then visually inspected and resulted in the selection of 10 compounds, 
S1–S10 (Table S1 and Fig. S3), for experimental testing.
Figure 1. Chemical structures of selected HKAIs. (A) F1 and F2 were identified in an in vitro screening of a 
fragment library by differential scanning fluorimetry as putative ligands of HK CA domain (Fig. S1A). (B) S5 
and S6 were identified in a SBVS for putative ligands of the CA domain of multiple HKs (Fig. S1B). (C) F1, F2, 
S5, and S6 were used as query molecules in ligand-based similarity searches (Fig. S1C) and F1.6, F1.8, F2.3, 
F2.4, F2.8, S1.7, S1.13, and S1.14 were among the hits showing promising in vitro activities (Tables 1 and 2).
Initial hits IC50 [mM]
MIC μg/ml
S. aureus S. epidermidis E. coli
Name PhoRS PhoRE HK853 WalK
DSM 
20231 DSM 20044 CFT 073
F1 n.d. 2 n.d. > 2 25 4 > 500
F2 n.d. 0.3 n.d. > 2 31 > 500 > 500
S1 > 5 > 5 > 5 > 5 > 500 > 500 > 500
S2 > 5 > 5 > 5 > 5 > 500 > 500 > 500
S3 > 5 > 5 > 5 > 5 > 500 > 500 > 500
S4 > 5 > 5 > 5 > 5 > 500 > 500 > 500
S5 ≈ 1 ≈ 1 > 5 > 1 > 500 500# > 500
S6 1.14 0.37 > 5 > 1 > 500 500# 500#
S7 < 5* > 5 > 5 > 5 > 500 > 500 > 500
S8 < 5* > 5 > 5 > 5 > 500 > 500 > 500
S9 > 5 > 5 > 5 > 5 > 500 > 500 > 500
S10 > 5 > 5 > 5 > 5 > 500 > 500 > 500
Table 1.  Selected compounds from the FBSS and SBVS and their corresponding IC50 and MICs.  
*% Inhibition at 5 mM ≥ 70%, i.e. IC50 < 5 mM. #MBC > 500 μ g/ml.
www.nature.com/scientificreports/
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The inhibitory activity of the 10 selected compounds from the SBVS on HK autophosphorylation was tested in 
vitro using four different HKs T. maritima HK853 (HK853), as a representative of the structures used in the dock-
ing assays, the highly extended HK PhoR from a Gram-negative (E. coli; PhoRE) and a Gram-positive (S. aureus; 
PhoRS) representative, and S. pneumoniae WalK (WalK) as a representative of the essential HKs29. As in the case 
of the fragments we performed initial in vitro kinase assays at a single and high compound concentration and at 
one time point (Fig. 3, Table 1). Autophosphorylation activity of HK853 was not or weakly (up to 30%) inhibited 
by the 10 compounds compared to the negative control (Fig. 3A) and it was not possible to identify more potent 
inhibitor(s) based on HK853 autophosphorylation inhibition. The kinase assays with WalK, PhoRE and PhoRS 
revealed that compounds S5 and S6 had a higher autophosphorylation inhibitory activity than the other selected 
compounds identified by SBVS and were general HKAIs (Fig. 3A, Table 1). S5 and S6 inhibit HK autophosphoryl-
ation activity in a dose-dependent manner, with IC50 in the high micromolar/ilimolar range (Fig. 3, Table 1). S5 
inhibits PhoRE, PhoRS and WalK with IC50 ≈ 1000 μ M and it seems it is not soluble in kinase buffer in the presence 
Figure 2. Biochemical evaluation by in vitro kinase assay of the FBS hits (F1 and F2) and their analogues 
(F1.1 to F1.9, and F2.1 to F2.10). (A) First, the autophosphorylation inhibitory activity was evaluated in a 
one concentration (2mM) one time-point (30 sec) in vitro kinase assays with WalK and PhoRE. The fragments 
inhibited WalK and PhoRE autophosphorylation with 10 to 62% and 17 to 80%, respectively. (B) IC50 of the 
more potent inhibitors (% inhibition at 2 mM > 50%) with antibacterial effect were measured in a multiple-
concentrations one time-point (30 sec) experiments.
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of 10% DMSO at concentrations higher than 1.3 mM. S6 inhibits PhoRE, PhoRS and WalK autophosphorylation 
with IC50 of 372 μ M, 1141 μ M and > 1000 μ M, respectively (Fig. 3, Table 1).
Furthermore, evaluation of the antibacterial effect of the 10 selected compounds from SBVS for the 
Gram-positive (S. aureus DSM 20231 and S. epidermidis DSM 20044) and Gram-negative (E. coli UCF 073) bacte-
ria, revealed that only S5 and S6 were able to inhibit bacterial growth at high compound concentrations, which is 
in agreement with their inhibitory activity on HKs (Table S2). S. epidermidis DSM 20044 growth was inhibited by 
S5 and S6 while E. coli UCF 073 growth was only inhibited by S6, in all the cases with modest MICs of 500 μ g/ml 
that are in line with the low HK affinity suggested by the measured IC50 (Fig. 3, Table 1). Both compounds were 
bacteriostatic against the three bacterial strains in the tested concentration range (MBC > 500 μ g/ml).
Ligand-based similarity searches identified more potent HKAIs with stronger antibacterial 
activity. It is a well-accepted assumption that similar compounds have similar activity; however, small struc-
tural changes in a compound can result in significant difference in potency (so called ‘activity cliffs’)51. The latter 
is exemplified by S5 and S6 since the two compounds are structurally similar but they show different inhibitory 
capacity toward the HKs assayed (Figs S1 and 1). On the basis of the reported initial results (i.e. in vitro and in 
silico screenings, biochemical enzyme inhibition and antibacterial susceptibility testing) and attempting to iden-
tify more potent HKAIs with stronger antibacterial effect, analogue compounds of F1, F2, S5 and S6 (Fig. 1) in 
the database from the Developmental Therapeutics Program of the National Cancer Institute and the National 
Strain
MIC (μg/ml)
F1 F1.6 F1.8 F2.3 F2.4 F2.8 S1.7 S1.13 S1.14
Staphylococcus aureus
 20231 25 125 125 125 250 31 250 8 500
 25293 125 250 250 125 125 250 125 8 125
 274/08 125 500 250 > 500 500 250 250 16 250
 V4180 125 > 500 250 250 500 250 > 500 8 250
 T4/6 125 250 250 250 > 500 250 250 8 250
 145/08 125 250 250 250 250 250 > 500 8 250
 127/08 n.d 250 250 250 500 250 > 500 16 250
 S908 n.d 500 250 250 500 n.d. > 500 16 250
Staphylococcus epidermidis
 20044 4 500 63 31 500 31 > 500 1 500
 RP62A > 500 > 500 500 125 > 500 250 > 500 8 > 500
 RP62A/1 250 > 500 250 125 n. d. 250 > 500 8 500
 T7/3 63 125 31 31 n. d. 63 > 500 8 250
 T37/8 > 500 > 500 500 125 n. d. 250 > 500 16 500
 T6119 > 500 > 500 250 125 n. d. 250 > 500 8 500
Streptococcus suis
 3881/S10 > 500 > 500 250 > 500 250 125 > 500 8 125
Streptococcus pneumoniae 
 49619 n. d. 256 128 4 64 n. d. 128 16 > 500
Acinetobacter baumannii
 NM109 n. d. n. d. 125 n. d. 500 n. d. > 500 > 500 250
 NM124 n. d. n. d. 125 n. d. 500 n. d. > 500 > 500 250
 NM8 > 500 > 500 125 > 500 500 > 500 > 500 > 500 500
 NM35 n. d. n. d. 125 n. d. > 500 n. d. > 500 > 500 500
 NM75 n. d. n. d. 250 n. d. > 500 n. d. > 500 > 500 500
Stenotrophomonas maltophilia
 B5/5 n. d. n. d. n. d. n. d. > 500 n. d. > 500 > 500 500
 B6/2 n. d. n. d. n. d. n. d. 500 n. d. > 500 > 500 500
 B32/1 > 500 > 500 > 500 > 500 500 > 500 > 500 > 500 500
Escherichia coli
 CFT 073 > 500 > 500 250 > 500 500 63 > 500 > 500 > 500
 ATCC 25276 > 500 > 500 250 > 500 500 500 > 500 > 500 > 500
Klebsiella pneumoniae
 ATCC700603 > 500 > 500 250 > 500 > 500 250 > 500 > 500 > 500
Pseudomonas aeruginosa
 ATCC 27853 > 500 > 500 500 > 500 > 500 > 500 > 500 > 500 > 500
Table 2.  Antibacterial activities of selected HKAIs for a panel of clinical isolates and reference strains. 
n.d.–not tested.
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Institute of Health (DTP) were identified using LBSS (i.e. by circular topological fingerprints as implemented in 
RDKit)52–54. The top 100 hits for the LBSS with the initial hits, F1, F2, S5 or S6 were visually investigated and a 
pool of 42 compounds (i.e. F1.1–F1.10, F2.1–F2.9, and S1.1–S1.25; Figs S1C, S4 and S5, Table S2) were experi-
mentally evaluated for their HK autophosphorylation inhibitory capacity and antibacterial effect in vitro.
First, inhibition of autophosphorylation was measured at a single time point (30 sec) using one concentration 
(2 mM) of each putative inhibitor. PhoRS and PhoRE were used as targets for the analogues of S5 and S6 since 
these HKs were more strongly inhibited by S5 and S6 compared to WalK and HK853. Compounds S1.1 to S1.25 
(2 mM) inhibited PhoRE and PhoRS autophosphorylation activity compared to the negative control from 6 to 85% 
and from 0 to 100%, respectively (Fig. 3 and Table S3). S1.2, S1.11, S1.13 inhibit autophosphorylation activity of 
both PhoRS and PhoRE with more than 75%. S1.7, S1.14 and S1.15 inhibit PhoRS and PhoRE autophosphorylation 
with more than 75% and more than 40% compared to the negative control, respectively (Fig. 3 and Table S3).
The F1 and F2 analogues inhibited WalK and PhoRE autophosphorylation activity compared to the negative 
control from 11 to 62% and 17 to 80%, respectively (Fig. 2 and Table S4). Only F1.6 inhibited WalK autophos-
phorylation by more than 50% at a concentration of 2 mM meaning that the remaining 18 of the tested F1 and F2 
analogues are weak (Ki ≫ 2 mM) WalK autophosporylation inhibitors. Inhibition of PhoRE autophosphorylation 
was greater than 50% for F1.8, F2.1, F2.2, F2.8 and F2.9 meaning that the remaining 12 of the tested compounds 
are weak PhoRE autophosphorylation inhibitors (Table S4).
The antibacterial effect evaluation of LBSS hits with two Gram-positive (S. aureus DSM20231 and S. epi-
dermidis DSM 20044) and one Gram-negative (E. coli CFT 073) strains showed that S1.7 was bacteriostatic for 
S. aureus DSM 20231 with a MIC of 250 μ g/ml (Table 2), S1.13 was bactericidal for S. aureus DSM 20231 and 
S. epidermidis DSM 20044 with MIC of 8 and 1 μ g/ml, respectively, and MBCs of 33 and 8 μ g/ml, respectively 
Figure 3. Autophosphorylation inhibitory activity of the initial hits from the SBVS (S1 to S10) and the 
analogues of S5 and S6, selected following LBSS. (A) One-time (30 sec) one-concentration (5 mM) kinase 
assay with the SBVS hits and PhoRS, PhoRE, WalK and HK853 distinguished S5 and S6 as relatively stronger 
multiple HKAIs. The IC50 for PhoRS, PhoRE and WalK in presence of S5 (B) and S6 (C) were calculated from the 
autophosphorylation reaction assays at different concentrations of compounds. (D) One-time point (30 sec), 
one-concentration (2 mM) kinase assay with the LBSS hits and PhoRS and PhoRE HKs. The IC50 for PhoRS and 
PhoRE in presence of S1.7 (E), S1.13 (F) and S1.14 (G) were calculated from the autophosphorylation reaction 
assays at different concentrations of compounds. Error bars represent the standard errors of the mean (SEM) of 
two independent assays with two replicates.
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(Table 2). Additionally, S1.14 was bactericidal for S. aureus DSM 20231 and S. epidermidis DSM 20044 at a MIC 
and MBC of 500 μ g/ml (Table 2). F1.6, F1.8, F2.3, F2.4 and F2.8 showed moderate antibacterial effects with 
MICs in the range of 31 to 250 μ g/ml for S. aureus DSM 20231 and 31 to 500 μ g/ml for S. epidermidis DSM 20044 
(Table 2). Only F1.8 and F2.8 had antibacterial effect on the Gram negative E. coli CFT 073 with MICs < 250 μ g/
ml. With the exception of F2.2 and F2.9, those compounds showing HK autophosphorylation inhibitory activity 
also showed antibacterial activity (Tables 2, S3 and S4), suggesting the possibility that the antibacterial activity 
might be mediated through the inhibition of HK autophosphorylation.
HK autophosphorylation is inhibited in a dose-dependent manner. The IC50 of the putative HK 
inhibitors (F2.2. and F2.9 were excluded since they did not show antibacterial effect, see below) were measured in 
a multiple concentrations at one time point (30 sec) kinase assays (Tables S3 and S4, Figs 2 and 3). F1.8 inhibited 
PhoRE autophosphorylation with IC50 ≤ 1 mM (reduced solubility in kinase buffer at concentrations higher than 
1 mM; Table S4, Fig. 2). F2.1 and F2.8 inhibited PhoRE autophosphorylation with IC50 0.24 and 0.72 mM, respec-
tively, (Table S4, Fig. 2). F2.1 and F2.8 showed good solubility in kinase buffer in the presence of 10% DMSO. 
S1.7 inhibits PhoRE autophosphorylation with IC50 in the lower micromolar range (≥ 100 μ M) and PhoRS in the 
higher micromolar/milimolar range (IC50 PhoRS ≥ 1000 μ M). The IC50 curves indicated that S1.7 is not soluble in 
concentrations higher than 1 mM in kinase buffer in the presence of 10% DMSO (Fig. 3, Table S3). S1.13 inhibits 
PhoRE and PhoRS with IC50 PhoRE = 16 μ M and IC50 PhoRS = 212 μ M and possess good solubility in kinase buffer 
in the presence of 10% DMSO (Fig. 3, Table S3). S1.14 IC50 against PhoRE and PhoRS is higher than 2000 μ M and 
higher than 1000 μ M, respectively (Fig. 3, Table S3).
The putative HKAIs showed antibacterial effects against multi-drug resistant clinical isolates. 
Next, we studied the antibacterial effect of F1, F1.6, F1.8, F2.3, F2.4, F2.8, S1.7, S1.13 and S1.14 on a panel of 
clinical isolates and reference strains of pathogenic bacteria (Tables 2 and S5). The methicillin-resistant S. aureus 
(MRSA) strains are well characterized and are resistant to all β -lactam antibiotics and a range of non-β -lactam 
antibiotics55. S. epidermidis clinical isolates were obtained from wounds of patients admitted to Tawam Hospital 
(Al Ain, United Arab Emirates). The clinical isolates of the Gram-negative Acinetobacter baumannii56 and 
Stenotrophomonas maltophilia57 are well characterized and show multi-drug resistance. Additional reference 
strains included the Gram-positive S. aureus ATCC 25293, S. epidermidis RP62A and RP62A, S. pneumoniae 
49619 and the emerging zoonotic pathogen Streptococcus suis 3881/S10, and the Gram-negative E. coli ATCC 
25276, Klebsiella pneumoniae ATCC 700603 and Pseudomonas aeruoginosa ATCC 27853.
F1 and F1.6 (halogen-substituted phenyl-thiazoleamines) showed similar antibacterial activities for the panel 
of clinical isolates and reference strains. Both F1 and F1.6 showed antibacterial effect for the MRSA strains (with 
the exception of F1.6 for V4180 MRSA strain) and S. aureus 25293 with MICs in the range of 125–500 μ g/ml 
(Table 2). V4180 MRSA strain is resistant to a wider range of antibiotics compared to the other MRSA strains 
tested (Table S5) including the small molecule antibiotics chloramphenicol and sulfamethaxazole. Given the 
broad range of antibiotic resistance of V4180 MRSA it is reasonable to propose that the presence of putative efflux 
pumps for small molecules could be responsible for the lack of susceptibility to F1.6. F1 and F1.6 showed antibac-
terial effect on one of the three tested S. epidermidis clinical isolates with MICs of 63 and 125 μ g/ml, respectively. 
F1.6 MIC for S. pneumoniae 49619 was 256 μ g/ml. F1 and F1.6 did not show antibacterial effect on S. suis 3881/
S10 or on any of the Gram-negative strains tested.
F1.8 (bromophenyl-pyrimidinediamine) showed antibacterial effect on all the Gram-positive strains tested. 
F1.8 MICs for the S. aureus reference strains and the MRSA strains were in the range of 125 to 250 μ g/ml. F1.8 
MICs for the S. epidermidis strains were in the range of 31 to 500 μ g/ml. F1.8 MICs for S. suis 3881/S10 and 
S. pneumoniae 49610 were 250 μ g/ml and 128 μ g/ml, respectively. F1.8 showed antibacterial effect for all the 
Gram-negative strains tested except for the S. maltophilia B32/1 strain. F1.8 MICs for the Gram-negative A. bau-
mannii strains, E. coli ATCC 25276 and K. pneumoniae ATCC 700603 were in the range of 125–250 μ g/ml and 
the MIC for P. aeruoginosa ATCC 27853 was 500 μ g/ml. In a similar way to F1.6 with V4180 MRSA, the lack of 
susceptibility of S. maltophilia B32/1 to F1.8 could be explained by the presence of efflux pumps. S. maltophilia 
B32/1 is also resistant to the small-molecule β -lactam antibiotic, meropenem so that efflux pumps with broad 
substrate specificity may be involved58.
The MICs of F2.3, F2.4 and F2.8 (substituted carbazoles) for the MRSA strains and S. aureus 25293 were in 
the range of 125–500 μ g/ml. F2.3 and F2.8 MICs for the S. epidermidis strains were in the range of 31–250 μ g/ml. 
F2.3 and F2.4 MICs for S. pneumoniae 49610 were 4 μ g/ml and 64 μ g/ml, respectively. F2.4 and F2.8 MICs for 
S. suis 3881/S10 were 125 and 250 μ g/ml, respectively. F2.3 and F2.8 did not show antibacterial effect for the A. 
baumannii and S. maltophilia strains. F2.4 MICs for three of the five A. baumannii strains and two of the three S. 
maltophilia strains tested were 500 μ g/ml. F2.4 and F2.8 MICs for E. coli ATCC 25276 were 500 μ g/ml. F2.8 MIC 
for K. pneumoniae ATCC 700603 was 250 μ g/ml. None of F2.3, F2.4 and F2.8 showed antibacterial effect for P. 
aeruginosa ATCC 27853.
S1.7 (N-[3-(2-chlorophenyl)phenyl]acetamide) inhibited the growth of two of the six MRSA strains in vitro 
with MICs ≥ 250 μ g/ml, which was comparable to the MICs for the S. aureus reference strains 25293 and DSM 
202231. The other four MRSA strains were not susceptible to S1.7. As expected from the results of the antibacte-
rial susceptibility testing with S. epidermidis DSM 20044, compound S1.7 had no antibacterial effect on the clin-
ical isolates of S. epidermidis. S1.7 inhibits the growth of all tested S. pneumoniae strains with MIC of 128 μ g/ml, 
which was similar to the MICs for the reference strains of S. aureus. S1.7 did not inhibit the growth of the S. suis 
3881/ S10 strain in the tested concentration range (≤ 500 μ g/ml). The strain specific antibacterial effects of S1.7 
correlate well with the quite different IC50 observed for PhoRE and PhoRS HKs.
S1.13 (4-[(3S,4R)-4-(4-fluorophenyl)hexan-3-yl]phenol) inhibited the growth of all tested MRSA stains with 
MICs between 8 and 16 μ g/ml (Table 2), which was comparable to the MICs for the reference strains of S. aureus. 
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S1.13 also inhibited the growth of clinical isolates of S. epidermidis with MICs between 8 and 16 μ g/ml, which 
is similar to the MICs for the biofilm forming S. epidermidis RP62A and non-biofilm forming S. epidermidis 
RP62A/1. Variation in MIC distributions for different strains of a species e.g. S. aureus is typical and reported76. 
Thus our finding that S. epidermidis 20044 has a MIC of 1 μ g/ml and the rest of the tested S. epidermidis strains 
have MICs between 8 and 16 μ g/ml is not unusual, but does indicate that some strains are more sensitive than 
others. When at least 100 strains are tested the MIC, which inhibits 50% of the isolates is typically considered the 
‘intrinsic resistance’ level of wild type isolates. Further studies on the further development of these inhibitors will 
include MIC assays on hundreds of isolates to calculate MIC50 and MIC90 values. Like S1.7, S1.13 inhibited the 
growth of the S. pneumoniae strains with MIC of 16 μ g/ml. S1.13 MICs against multi-drug resistant clinical iso-
lates are comparable with the MICs against reference strains. This suggests that the putative mechanism of action 
of S1.13 differs from the known antibiotics and/or the mechanisms of resistance of the tested strains to known 
antibiotics are not functional against S1.13.
S1.14 (4-tert-butyl-2-[(phenylamino)methyl]phenol) inhibits growth of MRSA with MICs of 250 μ g/ml, 
which was comparable to the MICs for the reference strains of S. aureus. S1.14 inhibited growth of all S. epider-
midis strains except S. epidermidis strain RP62A, with MICs in the range of 250 to 500 μ g/ml. S1.14 was not active 
against S. pneumoniae strains but inhibited growth of the S. suis S10 with MIC of 125 μ g/ml. S1.14 inhibits also 
the growth of the Gram-negative A. baumanii and S. maltohilia strains with MICs from 250 μ g/ml to 500 μ g/ml. 
S1.7, S1.13 and S1.14 did not inhibit the growth of K. pneumoniae ATCC 700603 and P. aeruginosa ATCC 27853 
at the highest tested concentration (MIC > 500 μ g/ml).
Increased antibacterial activity is not related to unspecific mechanism of action. Protein aggre-
gation and membrane damage have been described as mechanism of action of previously reported HKAIs59. To 
discard these mechanisms of action, protein aggregation activity of the hit compounds F1, F2, S5 and S6 was 
evaluated by native polyacrylamide gel electrophoresis using the catalytic portions (DHp and CA domains) of 
PhoRE as a target. Neither inhibitor caused protein aggregation when the compounds were added in high (2 mM) 
concentration (Fig. 4). Furthermore, similar assays carried out with additional HKs (PhoRS or EnvZ) or with the 
second generation compounds S1.7, S1.13 and S1.14, showed similar results (Fig. 4), suggesting that inhibitory 
activity of the compounds is unrelated with protein aggregation.
To check the potential of HK inhibitors to cause membrane damage60 hemolysis experiments with erythro-
cytes from a healthy donor were performed. Hemolysis was observed only with compound S1.13 at concentra-
tions higher than the observed MICs (LC50 277 μ g/ml). The rest of the tested inhibitors (S1.7, S1.14, F1, F1.6, 
F1.8, F2.3, F2.4 or F2.8) did not cause erythrocyte hemolysis at 500 μ g/ml (LC50 > 500 μ g/ml) indicating that the 
inhibitors do not cause loss of integrity of the erythrocyte plasma membrane at their MICs.
Inhibition of HK autophosphorylation is predicted to be mediated by interactions with key 
residues of the ATP-binding site of the HK CA domain. To get insights into the putative interaction 
mode of the reported HKAIs with the CA domains of HKs, molecular docking experiments were performed. The 
HKAIs (S5, S6, S1.7, S1.13, S1.14, F1, F1.6, F1.8, F2.3, F2.4, F2.8) and ADP as an internal control were docked to 
the CA domain of T. maritima HK853 (PDB: 3DGE) using the GOLD docking software61. The RMSD between the 
docked ADP and the cognate ADP structure in the HK853 was 1.0 Å. This corresponds to a successful re-docking 
calculation and, therefore, validates the used docking parameters. Due to low molecular weight of the HKAIs 
(Table S6), it is possible that the HKAIs possess more than one binding mode. Encouragingly, within the top 20 
solutions for each HKAI only one or two binding modes were predicted. This together with the low RMSD for the 
docked ADP gave us confidence about the predicted binding modes of the reported putative HKAIs.
A common feature for the predicted binding modes of all the compounds was the presence of an aromatic 
ring that accommodates into the hydrophobic cavity occupied by the pyrimidine ring of adenine (Fig. 5). The 
aromatic ring forms π –π stacking interactions with Y384 on one side and van der Waals contacts with I416 on 
Figure 4. (A) F1 and F2 (2 mM) do not cause HK aggregation as demonstrated by native-PAGE with E. coli 
PhoR (PhoRE) and EnvZ, and S. aureus PhoR (PhoRS). (B) Compounds S5 and S6 (5 mM), and S1.7, S1.13 and 
S1.14 (2 mM) do not cause HK aggregation as demonstrated by native-PAGE with PhoRS and PhoRE HKs.
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the other side of the ring. Similar hydrophobic interactions have been observed for the adenine in the structures 
of T. maritima HK853 and other HKs in complex with nucleotides62,32. Located at the bottom of the ATP-binding 
hydrophobic pocket is the conserved Asp (D411) in the G1 box that gives specificity for recognition of the N6 
amino group in the pyrimidine ring of adenine (Fig. 5). For S1.13, the most potent inhibitor, and S1.14, the 
hydroxyl group of the phenolic ring stacked in the adenine pocket is predicted to be hydrogen bonded to the 
conserved D411 residue. F1, F1.6, F1.8, F2.4, and F2.8 are also predicted to form polar contacts with D411 either 
by hydrogen bonds via classical hydrogen-donor groups (-OH, NH2) or by halogen atoms (e.g. Br, Fig. 5). Similar 
mode of interaction was observed for the binding of the Hsp90 inhibitor radicicol to the ATP-binding domain of 
the HK PhoQ63. The reported HKAIs are also predicted to interact with the ATP-lid, a variable loop involved in 
Figure 5. Predicted binding modes of selected HKAIs. All inhibitors (shown in blue as sticks) dock in 
the ATP-binding site of HK853 with a predicted binding mode resembling the experimental data (3DGE) 
from the natural product ADP (Top left). They interact with key elements involved in ATP-binding and 
autophosphorylation, i.e the N-, G1-, G2-boxes (shown in orange, blue and yellow, respectively) and the ATP-
lid (shown in red).
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nucleotide binding and autophosphorylation64,34, and with other conserved elements in the ATP-binding site such 
as the N- and G2-boxes. S5, S6 and S1.7 are predicted to exploit their common amide moieties to mediate polar 
interaction on the part of the active site, which in HK structures with the native ligand is occupied by the nucle-
otide phosphates and the Mg2+ cation. In the predicted binding modes of S5, S6, and S1.7, the nitrogen of the 
amide moiety is predicted to be hydrogen bonded to the conserved N-box Mg2+ chelating residue N380 whereas 
the oxygen is predicted to bind to the main-chain of the G2-Box residues G443, L444 and G445, mimicking in 
this way the interactions of the ATP γ -phosphate34. In addition, the docking experiments also predict that F1, 
F1.8, F2.3, F2.4 form hydrogen bonds with the ATP-lid (Fig. 5).
Overall, the predicted binding modes of the selected HKAIs indicate that main HKAI-HK interactions are 
mediated by hydrophobic ring stacking that are mimicking the adenine of the cognate ligand. Additionally, 
stabilizing interactions are formed with binding site residues that are conserved and are crucial for nucleotide 
selection and autophosphorylation, including D411 in the G1-box and residues in the N and G2-boxes, and the 
ATP-lid. This supports the in vitro results and suggests that the HKAIs possess general HK autophosphorylation 
inhibitory activity and also could inhibit further HKs not tested in this study.
S1.13 shows comparable in vitro activities to previously published HKAIs. Structure-based vir-
tual screenings for S. epidermidis WalK ligands yielded inhibitors, which were subsequently further optimized by 
rational design65. The last generation of S. epidirimids WalK inhibitors had MICs for S. epidermidis and S. aureus 
lower than 3.1 μ M, corresponding to MIC lower than 1.66 μ g/ml65. S1.13, the most potent HKAI reported here, 
possess MICs for S. epidermidis laboratory strains and clinical isolates in the range of 1 to 8 μ g/ml. S1.13 MICs for 
reference strains of S. aureus and clinical isolates of MRSA are in the range from 8 to 16 μ g/ml (Fig. 6, Table 2). 
Therefore, in terms of antibacterial activity S1.13 is comparable to the last generation of published S. epidermidis 
WalK inhibitors. The previous reported inhibitors showed IC50 values in the range of 24.2 to 71.2 μ M for the inhi-
bition S. epidermidis WalK autophosphorylation reaction65. S1.13 has not been tested for its autophosphorylation 
inhibitory capacity for any WalK, however, it inhibits PhoRE and PhoRS with IC50 of 16 and 212 μ M, respectively 
(Fig. 6, Table 2). Considering the differences in the experiments used to determine the IC50s of the S. epidermidis 
WalK inhibitors and S1.13 and the particular catalytic constants in the autophosphorylation reaction for each HK 
(e.g. Km for ATP has been reported from 2 to 200 μ M33), we can consider that all these inhibitors show a similar 
range (low micromolar) of autophosphorylation inhibitory activity. However, S1.13 (MW 272.4) is a relatively 
smaller compound compared to the last generation S. epidermidis WalK inhibitors (MW between 498.02 and 
534.02) implying that it possesses higher ligand efficiency and more possibilities for further optimization (Fig. 6).
Recently, Wilke and collaborators9 have reported a HTS of 53000 compounds for HKAIs that yielded a num-
ber of putative HKAIs. The best hit in terms of in vitro activities, compound 11, inhibits HK853 and S. pneumo-
niae VicK autophosphorylation with IC50 of 1.21 and 75 μ M, respectively (Fig. 6). The MICs for the Gram-positive 
B. subtilis and the Gram negative E. coli DC2 were in the range of 49–64 and 32–64 μ g/ml respectively. S1.13 
was not active against any Gram-negative strain tested (Table 2), however, the MICs against the Gram-positive 
strains tested were 2 to 8 times lower than the MIC of compound 11 for B. subtilis. The latter supports that 
structure-based and fragment-based approaches present an efficient way for generation of hits for putative HK 
autophosphorylation inhibitors that can be further used in antibacterial drug discovery following hit-to-lead opti-
mization. Furthermore, S1.13 has been recently tested in the NCI/DTP One Dose/ 60 cell line screen (NCI-60)52. 
NCI-60 includes a collection of tumor cell lines derived from a variety of human adult cancer tissue types and 
is commonly used for genetic analysis and screening of potential chemotherapeutic agents. 2.72 μ g/ml (10 μ M) 
of S1.13 did not inhibit the growth of any of the cell lines with more than 19%, and most of the cell lines growth 
was not inhibited66. Finally, the analysis of inhibitors databases as well as the current bibliography indicated that 
the scaffold of S1.13, as well as the scaffolds of S1.7 and F1.8, had not been previously proposed as antibacterial 
agents, pointing to these compound as a promising starting point for the development of broad-spectrum anti-
bacterials with polypharmacology effect.
SBVS and in vitro screenings alone or in combination yield promising hits for antibacterial drug 
discovery. The growing problem of MDR has motivated efforts in antibacterial drug discovery in recent years 
and different essential and non-essential targets absent in mammals have been explored67. For example, the essen-
tial CDP-ME kinase (IspE) contributes to the non-mevalonate or deoxy-xylulose phosphate (DOXP) pathway for 
isoprenoid precursor biosynthesis found in many species of bacteria and apicomplexan parasites. Tidten-Luksch 
and collaborators employed a in silico and in vitro screenings against IspE to identify non-substrate like inhibi-
tors67. The two strategies were complementary, delivering chemically distinct hits with in vitro biochemical activ-
ities in the high micromolar to low millimolar range for the in silico screening hits, and in the low micromolar 
range for the in vitro screening hits. The success rate (size of starting library/ number of hits for which IC50 could 
be measured) was < 0.01% for the in silico screening and 0.03% for the in vitro screening67. Similarly, the approach 
reported here to identify putative HKAIs comprising SBVS and FBS, followed by LBSS, yielded distinct scaffolds 
with IC50 in the micromolar to low milimolar range and antibacterial effect in vitro. The success rate for the SBVS 
was < 0.01%, and 0.2% for the FBS, confirming that different approaches result in comparable success rates in 
identifying hits for antibacterial drug discovery.
Summary. Here we report the identification of putative bacterial HKAIs with broad-spectrum antibac-
terial effect against both Gram-positive and Gram-negative pathogens using a combination of in silico and in 
vitro screens. The most potent hit, S1.13, is bactericidal against Gram-positives, including multi-drug resist-
ant MRSA, with MBCs ≤ 16 μ g/ml. The MICs of S1.13 for Gram-positive bacteria are higher than the MICs of 
the recently published promising antimicrobial teixobactin (0, 06–4 μ g/ml)68. Nevertheless, the much smaller 
molecular weight (S1.13 272.4 vs. teixobactin 1242.47), relatively simpler chemical structure, drug-like 
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physicochemical properties, and the expected polypharmacology effect make S1.13 a very promising hit for devel-
opment of novel antibacterials to treat Gram-positive infections. The antibacterial effects of the reported hits against 
E. coli (F1.8 ≥ 250 μ g/ml and F2.8 ≥ 63 μ g/ml) are negligible when compared to teixobactin (2–25 μ g/ml). Both 
the reported HKAIs and teixobactin are not active against P. aeruginosa and K. pneumoniae. Nevertheless, HKAIs 
are targeted at intracellular targets, namely the CA domains of HKs, and were shown to inhibit the autophospho-
rylation of HKs from Gram-negative bacteria (i.e. PhoRE). This implies that their antibacterial activity against 
Gram-negatives could be improved by medicinal chemistry or delivery methods that facilitate passage of the 
inhibitor through the outer membrane. This would also make HKAIs a promising starting point for the develop-
ment of antibacterials with polypharmacology against Gram-negatives. Teixobactin is proposed to interfere with 
one of the membrane-associated steps of peptidoglycan biosynthesis. Although resistance development to teixo-
bactin has not been detected68, resistance to antimicrobials with similar mechanism of action (e.g. vancomycin) is 
well-known. In conclusion, the reported HKAIs show comparable in vitro activities to previously reported HKAIs 
and comparable future potential to recently discovered antimicrobials to be further developed as broad-spectrum 
antibacterials.
Figure 6. Comparison of S1.13 and previously reported HKAIs. (A) S1.13 inhibits the autophosphorylation 
of HK from a Gram positive (PhoRS) and a Gram negative (PhoRE) species with IC50 of 212 and 16 μ M, 
respectively, shows antibacterial effect against Gram positive strains with MICs ≥ 8 μ g/ml, and has a MW < 300, 
indicating a high potential for improvement. (B) H2-81 (MW 500) was derived from previously reported HKAI 
following rational design65, inhibits S. epidermidis YycG with IC50 = 24 μ M, and shows antibacterial effect 
against Gram positive strains with MICs ≥ 0.75 μ g/ml. (C) Compound 11 (MW 314) was identified in a high-
throughput screening for HKAIs9, inhibits T. maritima HK853 and S. pneumoniae VicK autophosphorylation 
with IC50 of 1.21 μ M and 75 μ M, respectively, and shows antibacterial effect against both Gram positive and 
Gram negative bacteria with MICs ≥ 49 and MICs ≥ 32, respectively.
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Materials and Methods
Reagents. A fragment library of 898 compounds (> 95% purity) was purchased from Chem-X-Infinity 
(Romanville, France) and the individual compounds were stored at − 80 °C at a concentration of 20 mM. For 
screening purposes, cocktails of 10 compounds at final concentration of 2 mM were prepared in a 96-well-plate. 
Re-supply of compounds F2 and F2.5 to F2.9 (Table S2) were purchased from Sigma-Aldrich (Spain). Re-supply 
of F1 was purchased from Apolo Scientific (United Kingdom). Compounds F1.1 to F1.10 and F2.1 to F2.3 (Table 
S2) were obtained from Developmental Therapeutics program of the National Cancer Institute and the National 
Institute of Health (DTP NCI/NIH)52. Compounds S1 to S10 from the initial SBVS screening were purchased 
from Ukrainian Organic Synthesis (Kiev, Ukraine). Compounds S1.1 to S1.25 from the ligand-based similar-
ity searches (LBSS) were obtained from DTP. γ -32P-ATP was purchased from Perkin Elmer. Compounds were 
dissolved in 100% DMSO and stored at 4 °C protected from direct light. [γ -32] ATP was purchased from Perkin 
Elmer.
Cloning, expression and purification. S. pneumoniae walK encoding the catalytic portion (DHp and 
CA domain) of WalK (amino acids from 208 to 449) was amplified by PCR from S. pneumoniae CDC3059-06 
genomic DNA using the following primers: forward 5′ -aagttctgtttcagggcccgatggagcaggagaaggaagaacgc-3′ and 
reverse 5′ -atggtctagaaagctctagtcttctacttcatccac-3′ . The PCR product was purified by PCR product purification 
kit (Macherey-Nagel) and cloned into a gel-purified pOpinF vector (kindly provided by Nick Berow, IRB, Spain) 
linearized with KpnI and HindIII (Fermentas). The insert was cloned into the pOpinF vector with InFusion HD 
cloning system (Clontech). Positive clones were confirmed by colony PCR and DNA sequencing.
S. pneumoniae WalK (WalK) was expressed in E. coli RIL. Luria Broth (LB) media supplemented with 100 μ g/ml 
ampicillin and 33 μ g/ml chloramphenicol was inoculated with an overnight pre-culture (1/50 of the culture vol-
ume). At exponential phase (OD600 0.2–0.4) protein expression was induced by addition of 1 mM IPTG for 3 
to 5 h at 37 °C. The cells were harvested by centrifugation at 4000 g, 4 °C for 25 min and the pellets were stored 
at − 80 °C until use. The cell pellets were resuspended in lysis buffer (100 mM Tris pH 8.0, 150 mM NaCl, 0.1 mM 
PMSF) and sonicated at 4 °C for 5 min at pulses of 15 sec every 1 minute The cell debris and the supernatant 
were separated by centrifugation at 11000 g, 4 °C for 60 min. The cell debris were resuspended in equilibration 
buffer (100 mM Tris pH 8.0, 150 mM NaCl) containing 2 M urea and incubated overnight at 4 °C with rotation. 
After centrifugation at 11 000 g, the supernatant was injected into a Ni-affinity chromatography column (GE 
Healthcare) equilibrated with equilibration buffer, washed with 5 volumes of equilibration buffer and eluted with 
equilibration buffer containing 0.5 M imidazole. WalK was concentrated with AmiconUltra (Millipore, USA) 
centrifugal filters, aliquoted and stored at − 80 °C until use. The yield was ≤ 0.5 mg/L culture.
The catalytic portion (DHp and CA domain) of E. coli PhoR (PhoRE), E. coli EnvZ, and S. aureus PhoR 
(PhoRS), and the CA domain of Synechococcus sp. PCC 7942 NblS were expressed and purified as previously 
described34,64,69,70. Shortly, proteins were expressed in E. coli RIL and purified by Ni-affinity and size-exclusion 
chromatography. Purified proteins were stored in 20–50 μ l aliquots at − 80 °C.
Structure-based virtual screening. Target preparation. The chosen molecular targets for molecular 
docking were the CA domains of Thermotoga maritima HK853 (PDB: 3DGE)64, Geobacillus stearothermophillus 
KinB (PDB: 3D36)44 and T. maritima CheA (PDB: I58B)43. Residues corresponding to the CA domain of each A 
chain (320–480 for 3DGE , 270–415 for 3D36 and 354–540 for I58B) were selected for each structure and addi-
tional atoms corresponding to water molecules, ions or ligands were removed. Hydrogen atoms were added in the 
absence of the cognate ligand using the GOLD program61.
Docking parameters. All docking calculations were performed with the GOLD docking software (version 5.2) 
using ChemPLP as a scoring function49. Binding sites were defined as being 10 Å around the geometric centre of 
the cognate ligand.
Library. For the initial screening, a diversity set (600 000) of the Scopius–CSpace database (over 6 million com-
mercially available drug-like compounds)71 (http://inhibox.com), was docked into each of the three HK struc-
tures. The search efficiency parameter was set to 30%, 10 solutions were generated for each compound of which 
only the highest-scoring poses were saved.
Post-processing of docking results. Compounds with unwanted functional groups (in-house rules used by 
InhibOx) were removed and the resulting set of compounds was ranked in two lists: i) by the ChemPLP GOLD 
docking score (ChemPLP) and ii) by a ligand efficiency score (l.e.) which is ChemPLP divided by the number 
of non-hydrogen atoms in the compound50. The top 3500 compounds in each list were used to extract the top 
100 compounds docking to all three HKs CA domain structures. This resulted in two final lists of compounds: 
one with respect to ChemPLP and one with respect to ligand efficiency. The top 100 compounds of each list were 
finally visually inspected and ten compounds were purchased for experimental testing.
Ligand-based similarity searches. The database from the Developmental Therapeutics program of the 
National Cancer Institute and the National Institute of Health (DTP)52 was searched for analogue structures of 
the initial hits F1, F2, S5 and S6. The similarity searches with F1, F2, S5 and S6 as query molecules were performed 
using the Morgan fingerprint as implemented in RDKit54, which is a variation of the “extended connectivity 
fingerprints” (ECFP)53. The top 100 hits of each similarity search were visually inspected of which in total 25 
compounds were ordered and experimentally tested.
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Binding mode prediction. Docking calculations to predict the binding modes of the reported fragments 
were performed using the ATP-binding domain of T. maritima HK853 (PDB: 3DGE, chain A, residues from 270 
to 415) and the GOLD docking software61. For each ligand 100 solutions were generated of which the top 20 were 
visually inspected. In Fig. 5 the dominant binding mode within the top 20 solutions is shown for the respective 
ligand.
Differential scanning fluorimetry. To monitor protein unfolding, the fluorescent dye Sypro orange 
was used26. Differential scanning fluorimetry (DSF) experiments were conducted in the iCycleriQ Real Time 
Detection System (Bio-Rad, Hercules, CA). Solutions of 20 μ l of 0.1 mg/ml protein (final concentration), 200 μ M 
fragment cocktails or individual fragments (final concentration), 10X sypro orange (final concentration) and 
buffer (100 mM TrisCl pH 8, 150 mM NaCl) were added to the wells of the 96-well iCycler iQ PCR plate. The plate 
was heated from 20 to 85 or 99 °C at a heating rate of 1 °C/min. The fluorescent intensity was measured with Ex/
Em: 490/530 nm. Prism GraphPad v.5 was used for curve fitting and statistical analysis72.
Kinase assay. To evaluate the inhibitory capacity of selected hits from DSF, SBVS and LBSS in vitro auto-
phosphorylation kinase assays with γ -32P-ATP were performed as previously described62. Ligands were dissolved 
in 100% DMSO. When comparing the inhibitory capacity of ligands in one concentration-one time point exper-
iments or when measuring IC50 (the concentration at which 50% residual HK autophosphorylation activity is 
observed), the final DMSO concentration in the assays was 10% (v/v). Controls lacking ligands contained an equal 
concentration of DMSO. Inhibition of autophosphorylation was determined by incubating 0.12 mg/ml (≈ 4 μ M) 
HK and up to 20 mM fragment in kinase buffer (50 mM Tris HCl, pH 8.5, 50 mM KCl, 5 mM MgCl2, 0.5 mM 
EDTA and 0.1 mM DTT). Autophosporylation reactions were initiated by addition of 0.1 μ Ci/μ l γ -32P-ATP con-
taining from 0.03 to 0.06 μ M ATP (final concentrations). Autophosphorylation was quenched with 2xSDS-PAGE 
sample buffer supplemented with 50 mM EDTA. Samples were applied without heating to 15% (w/v) Tris-glycine 
SDS-polyacrylamide gels. After electrophoresis, the bottoms of the gels were removed to lower the background 
from the unincorporated radiolabeled ATP. Gels were dried without staining on a Bio-Rad Gel Air drying system 
and the phosphorylated protein was quantified by phosphor-imaging. Prism GraphPad was used for curve fitting 
and statistical analysis72.
Aggregation analysis by native polyacrylamide gel electrophoresis. E. coli PhoR and EnvZ, and S. 
aureus PhoR (0.12 μ g/ml, final concentration) were prepared in kinase buffer. Compounds were added to a final 
concentration of 5 mM (S5 and S6) or 2 mM (F1 and F2, S1.7, S1.13, S1.14). DMSO in the assays was maintained 
to a final concentration 10% (v/v). After 30 min of incubation at room temperature Native polyacrylamide gel 
electrophoresis (Native-PAGE) loading buffer was added and samples loaded. Coomassie blue staining was used 
for protein visualization.
Antibacterial susceptibility testing. Bacterial strains used in this study for antibacterial susceptibility 
testing (Table S5) were propagated using standard microbiological procedures. Minimal inhibitory concentra-
tions (MICs) were determined following a standard double-dilution method73. MICs were recorded as the lowest 
concentration of the compound where no visible growth was observed. After plating the dilutions around the 
MIC or growing them in fresh MH media, minimal bactericidal concentration (MBC) was recorded as the lowest 
concentration of the compound at which no colonies were formed or no growth was observed, respectively. For 
S. pneumoniae MICs were determined by adapting the standard double-dilution method to anaerobic conditions 
and of this microorganism (use of Todd Hewitt Yeast extract with 200 U/mL of catalase and continuous moni-
toring of growth). MBCs for S. pneumoniae were determined by inoculation of 10 μ l from each well that did not 
shown visible bacterial growth on THY 0,5% 3% blood agar plates. After 24 h of incubation at 37 °C 5% CO2, 
the first dilution yielding three colonies or fewer was scored as the MBC, as described by the CLSI for starting 
inoculate of 1 × 105 CFU/ml74.
Hemolysis assay. Hemolytic activity against human erythrocytes taken from a healthy donor was meas-
ured as previously described73. The hemolysis experiments were carried out in accordance with the guidelines of 
the United Arab Emirates University (UAEU) Research Ethics Review Board. All experimental protocols were 
approved by the Research Ethics Review Board of UAEU and informed consent was obtained from all donors.
Erythrocytes were incubated with (up to) 500 μ g/ml compounds and the LC50 value was recorded as the mean 
concentration of compound producing 50% hemolysis in three independent incubations.
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